Cas:69467-09-0 5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine manufacturer & supplier

Chemical Name:5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine

CAS.NO:69467-09-0

Synonyms:5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine

Molecular Formula:C₁₂H₉N₃O₂S

Molecular Weight:259.28400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:411.7ºC at 760mmHg

Density:1.41g/cm3

Index of Refraction:1.654

PSA:90.25000

Exact Mass:259.04200

LogP:3.11350

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine Use and application,5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine technical grade,usp/ep/jp grade.

Related News: The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma��s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution. 5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine manufacturer Physiologically relevant interactions with test molecules or protein ligands can be identified with high sensitivity and specificity. 5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine supplier Physiologically relevant interactions with test molecules or protein ligands can be identified with high sensitivity and specificity. 5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine vendor The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations. 5,6-bis(furan-2-yl)-3-methylsulfanyl-1,2,4-triazine factory In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.